GlaxoSmithKline has announced that generic carvedilol phosphate (Coreg CR) extended-release capsules, a once-a-day beta blocker, is now available nationwide. Approved in 2006, canadian Coreg CR is indicated for treating hypertension, post-myocardial infarction left ventricular dysfunction, and mild-to-severe heart failure. Patients previously had to take the drug twice a day.
Coreg CR is available in strengths of 10 mg, 20 mg, 40 mg, and 80 mg.
This is the first FDA-approved medication that uses Flamel’s Micropump technology, which controls delivery of the drug over a 24-hour span.